Inflammation-related gene

• US 20020187947A1
• Filed: 03/02/2001
• Published: 12/12/2002
• Est. Priority Date: 03/06/2000
• Status: Abandoned Application

• Current Assignee: Gabor Jarai, Paul Roy Cooper, Shida Yousefi
• Original Assignee: Gabor Jarai, Paul Roy Cooper, Shida Yousefi
• Inventors: Cooper, Paul Roy, Jarai, Gabor, Yousefi, Shida
• Application Number:
  US09/798,710
• Publication Number:
  US 20020187947A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/16 Central respiratory analeptics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

The use of (A) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a functionally equivalent variant of that amino acid sequence, or (B) a polynucleotide comprising a nucleotide sequence encoding the polypeptide (A), or (C) an antibody which is immunoreactive with the polypeptide (A), or (D) an antisense oligonucleotide comprising a nucleotide sequence complementary to that of polynucleotide (B), or (E) a polynucleotide probe comprising at least 15 consecutive nucleotides of (B), in a pharmaceutical for the diagnosis or treatment of a neutrophil-associated inflammatory disease.

Claims

1. A method of treating a neutrophil-associated inflammatory disease which comprises administering to a subject in need thereof an effective amount of a pharmaceutical comprising (A) a polypeptide comprising the amino acid sequence of SEQ ID NO:

2, or a functionally equivalent variant of said amino acid sequence, or (B) a polynucleotide comprising a nucleotide sequence encoding the polypeptide (A), or (C) an antibody which is immunoreactive with the polypeptide (A), or (D) an antisense oligonucleotide comprising a nucleotide sequence complementary to that of polynucleotide (B).

2. A method according to claim 1 in which the pharmaceutical is a polypeptide (A) comprising a consecutive 10 amino acid portion identical in sequence to a consecutive 10 amino acid portion of SEQ ID NO:

2.

3. A method according to claim 1 in which the pharmaceutical is a polynucleotide (B) which is cDNA comprising the nucleotide sequence of SEQ ID NO:

1, or a DNA comprising a nucleotide sequence which hybridises to SEQ ID NO;

1 under stringent conditions.

4. A method according to claim 3 in which the polynucleotide (B) comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of SEQ ID NO:

1.

5. A method according to claim 3, in which the polynucleotide (B) comprises a portion having at least 50 contiguous bases from SEQ ID NO:

1.

6. A method according to claim 1 in which the pharmaceutical is an antisense oligonucleotide (D) comprising a nucleotide sequence complementary to that of SEQ ID NO:

1.

7. A method according to claim 1, in which the disease is chronic obstructive pulmonary disease, adult respiratory distress syndrome, rheumatoid arthritis or inflammatory bowel disease.

9. A method of diagnosing a neutrophil-associated inflammatory disease in a subject comprising detecting the presence of a polynucleotide (B) as specified in claim 1 in a cell or tissue from the subject which comprises contacting DNA from the cell or tissue with a polynucleotide probe comprising at least 15 contiguous nucleotides of a polynucleotide (B) under conditions where the probe is specifically hybridizable with a polynucleotide (B) and detecting whether hybridization occurs.

10. A method according to claim 9, in which the polynucleotide (B) comprises the nucleotide sequence of SEQ ID NO:

1 or a sequence which hybridises to SEQ ID NO;

1 under stringent conditions.

11. A method according to claim 10, in which the polynucleotide (B) comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of SEQ ID NO:

1.

12. A method according to claim 10, in which the polynucleotide (B) comprises a portion having at least 50 contiguous bases from SEQ ID NO:

1.

13. A method of determining whether a subject has, or is likely to develop, a neutrophil-associated inflammatory disease which comprises determining the level of a polypeptide (A) or a polynucleotide (B) as specified in claim 1 in cell or tissue from the subject, or determining a bioactivity of (A) in a cell or tissue from the subject or determining the presence of a mutation in (B) in a cell or tissue from the subject, and comparing the result with that obtained from a healthy subject.

14. A method according to claim 13, in which the polypeptide (A) comprises a consecutive 10 amino acid portion identical in sequence to a consecutive 10 amino acid portion of SEQ ID NO:

2.

15. A method according to claim 13, in which the polynucleotide (B) comprises the nucleotide sequence of SEQ ID NO:

1 or a sequence which hybridises to SEQ ID NO;

1 under stringent conditions.

16. A method according to claim 15, in which (B) comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of SEQ ID NO:

1.

17. A method according to claim 15, in which (B) comprises a portion having at least 50 contiguous bases from SEQ ID NO:

1.

18. A method of identifying a substance suitable for use in treatment of a neutrophil-associated inflammatory disease which modulates an activity of a polypeptide (A) as specified in claim 1 which comprises combining a candidate substance with said polypeptide (A) and measuring the effect of the candidate substance on said activity of (A).

19. A method according to claim 18, in which the disease is chronic obstructive pulmonary disease, adult respiratory distress syndrome, rheumatoid arthritis or inflammatory bowel disease.

20. A method of identifying a substance suitable for use in treatment of a neutrophil-associated inflammatory disease which comprises combining a candidate substance with a polypeptide (A) as specified in claim 1 and determining whether binding has occurred.

8. A method of detecting a predisposition to developing a neutrophil-associated inflammatory disease in a subject which comprises incubating a genetic sample from the subject with a polynucleotide probe (E) comprising a nucleotide sequence complementary to that of SEQ ID NO:

1 under conditions where the probe hybridises to complementary polynucleotide sequence, to produce a first reaction product, and comparing the first reaction product to a control reaction product obtained with a normal genetic sample, where a difference between the first reaction product and the control reaction product indicates a predisposition to developing a neutrophil-associated inflammatory disease.